WARREN, N.J., Jan. 25, 2019 /PRNewswire/ -- Aquestive
Therapeutics, Inc. (Nasdaq: AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated
products to solve therapeutic problems, today announced that the U.S. District Court for the District of New Jersey has
granted a temporary restraining order (TRO) that enjoins Alvogen from initiating any launch activities related to its generic
buprenorphine/naloxone sublingual film. This TRO will remain in place pending a hearing on the preliminary injunction (PI) motion
previously filed by Aquestive and Indivior PLC (LON: INDV). The hearing on the PI motion is scheduled with the District
Court on February 7, 2019.
The '305 patent for SUBOXONE® Sublingual Film, held by Aquestive and Indivior, remains the subject of ongoing
patent infringement litigation regarding generic buprenorphine/naloxone sublingual films.
"We are pleased that the Court has granted our request for a temporary restraining order. We are continuing to work with
Indivior to assert and protect our intellectual property embedded in SUBOXONE," said Keith
Kendall, CEO of Aquestive Therapeutics. "Despite multiple alternative products in the market over the last several years,
SUBOXONE Sublingual Film remains the market leader, and we are confident that it will continue to thrive based on the proven
track record the product has in addressing patient needs and preferences for treatment."
About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company that applies innovative technology to solve
therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to
treat CNS conditions and provide alternatives to invasively-administered standard of care therapies. The company also
collaborates with pharmaceutical partners to bring new molecules to market using proprietary, best-in-class technologies, like
PharmFilm®, and proven capabilities for drug development and commercialization.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential,"
"project," "will," "would," or the negative of those terms, and similar expressions, are intended to identify forward-looking
statements. Such statements include, but are not limited to, statements about regulatory approvals and pathways, clinical trial
timing and plans, the achievement of clinical and commercial milestones, future financial and operating results, business
strategies, market opportunities, financing, and other statements that are not historical facts.
These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such
risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any
delays or changes to the timing, cost and success of our product development activities and clinical trials; the risks of delays
in FDA approval of our drug candidates or failure to receive approval; the risks inherent in commercializing a new product
(including technology risks, financial risks, market risks and implementation risks and regulatory limitations); development of
our sales and marketing capabilities; issues related to the outsourcing of certain operational and staff functions to third
parties; the rate and degree of market acceptance of our product candidates; the success of any competing products; the size and
growth of our product markets; the effectiveness and safety of our product candidates; risks associated with intellectual
property rights and infringement, including the outcome of patent infringement litigation relating to the Company's products
(including the ongoing ANDA lawsuits); unexpected patent developments; the impact of existing and future legislation and
regulatory provisions on product exclusivity; legislation or regulatory action affecting pharmaceutical product pricing,
reimbursement or access; claims and concerns that may arise regarding the safety or efficacy of the Company's products and
product candidates; risks related to legal proceedings, including ongoing investigative and antitrust litigation matters; changes
in governmental laws and regulations; the impact of product recalls and withdrawals; uncertainties related to general economic,
political, business, industry, regulatory and market conditions and other unusual items; and other risks and uncertainties
affecting the Company including those described in the "Risk Factors" section included in the Company's Quarterly Report on Form
10Q for the period ended September 30, 2018, filed with the Securities and Exchange Commission
(SEC) on November 6, 2018, and the risk factors discussed in our prospectus dated July 24, 2018, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933. Given these
uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All
subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their
entirety by this cautionary statement. We assume no obligation to update our forward-looking statements after the date of this
press release whether as a result of new information, future events or otherwise, except as may be required under applicable
law.
Media inquiries:
Christopher Hippolyte
christopher.hippolyte@syneoshealth.com
212-364-0458
Investor inquiries:
Stephanie Carrington
stephanie.carrington@icrinc.com
646-277-1282
View original content to download multimedia:http://www.prnewswire.com/news-releases/aquestive-therapeutics-granted-temporary-restraining-order-tro-against-alvogen-300784410.html
SOURCE Aquestive Therapeutics, Inc.